ResultsIQ › Latest results › Quick Heal Technologies Limited
Quick Heal Technologies Limited Q2 FY27 earnings call summary
NSE: QUICKHEAL · BSE: 539678
Earnings call of 28 Oct 2026, summarised by AI from the filing.
Consumer revenue fell 40% YoY to ₹36 cr as credit controls were tightened.
Key takeaways
- Consumer decline Consumer revenue fell 40% YoY to ₹36 cr as credit controls were tightened.
- Enterprise wins Strategic wins across defence, BFSI and a large IT services company through new-generation products.
- Microsoft risk Microsoft's default free antivirus and removal of expired versions is the biggest challenge for antivirus vendors.
Quick Heal Technologies Limited Q2 FY27 results
As filed: Revenue ₹64.9 cr (−23% year on year), EBITDA ₹2.3 cr (−74% year on year), PAT ₹5.8 cr (−28% year on year), EBITDA margin 3.5% (−717 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹45.0 cr (−21% year on year), EBITDA −₹17.6 cr, PAT −₹5.3 cr, EBITDA margin -39.1% (−1,000 bps). Score 28 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 8% from last quarter. Share price after the results: −12.7% in 29 days (Nifty 500: +0.7%).
- Q4 FY26: Revenue ₹48.7 cr (−25% year on year), EBITDA −₹29.3 cr, PAT −₹19.9 cr, EBITDA margin -60.2% (−1,000 bps). Score 15 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 32% from last quarter. Share price after the results: −16.0% in 29 days (Nifty 500: +2.4%).
- Q3 FY26: Revenue ₹71.5 cr (+1% year on year), EBITDA ₹0.5 cr, PAT ₹6.6 cr, EBITDA margin 0.6% (+626 bps). Score 37 of 100, Below trend. Revenue growth was below the company's own trend. EBITDA margin rose 626 bps year on year. Other income 156% of PBT. Tax rate -15%. Revenue fell 15% from last quarter. Share price after the results: −11.9% in 29 days (Nifty 500: +0.1%).
- Q2 FY26: Revenue ₹84.0 cr (+15% year on year), EBITDA ₹9.0 cr (+200% year on year), PAT ₹8.0 cr (+100% year on year), EBITDA margin 10.7% (+660 bps). Score 72 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 660 bps year on year. Other income 40% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −6.9% in 30 days (Nifty 500: +2.0%).
- Q1 FY26: Revenue ₹57.0 cr (−19% year on year), EBITDA −₹10.0 cr (−300% year on year), PAT −₹6.0 cr (−250% year on year), EBITDA margin -17.5% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 12% from last quarter. Share price after the results: −0.2% in 29 days (Nifty 500: +0.6%).
- Q4 FY25: Revenue ₹65.0 cr (−19% year on year), EBITDA −₹9.0 cr (−190% year on year), PAT −₹3.0 cr (−121% year on year), EBITDA margin -13.9% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 8% from last quarter. Share price after the results: +39.0% in 30 days (Nifty 500: +4.5%).
- Q3 FY25: Revenue ₹71.0 cr (−13% year on year), EBITDA −₹4.0 cr (−133% year on year), PAT ₹0.0 cr (−100% year on year), EBITDA margin -5.6% (−1,000 bps). Score 18 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin fell 1000 bps year on year. Profit fell 100% from last quarter.
Past price moves after results do not indicate future moves. Not a recommendation.
Quick Heal Technologies Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (28 Oct 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.